Alibaba Health Information Technology Ltd (HKG: 0241), based in China, has released its financial results for the first half of 2023, ending September 30, reporting revenues of RMB 12.956 billion. This represents a year-on-year increase of 12.7%, driven by robust growth in its pharmaceutical self-operated business as well as its medical and digital health services.
The pharmaceutical self-operated segment, which encompasses B2C retail, relevant advertising, and B2B centralized procurement distribution, generated RMB 11.4 billion in sales, reflecting a 13.5% year-on-year growth. This growth was fueled by an expanded range of self-operated retail products, strengthened partnerships with pharmaceutical companies, and enhanced user experiences through improved information security and professional consulting services.
The pharmaceutical e-commerce platform, which includes categories such as pharmaceuticals, health food, medical devices, and more, contributed RMB 1.02 billion, marking a 2.1% increase year-on-year. This segment includes businesses acquired from Alibaba Group and outsourcing services for the Tmall pharmaceutical platform, excluding acquired categories.
During this period, Alibaba Health continued to enhance its healthcare professional service offerings, providing integrated online and offline medical services through platforms like Taobao, Tmall, Alipay, and others. The company’s drug tracking platform, mashangfangxin.com, also showed steady growth. The medical health and digital service business generated RMB 488 million, up 16.4% year-on-year.- Flcube.com
